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Synthesis and photodegradation studies of analogues of muscle 
relaxant 1,4-dihydropyridine compounds
This paper describes the synthesis of 1,4-dihydropyridine 
compounds (DHPs) endowed with good muscle relaxant 
activity and stability to light. Six new condensed DHPs 
were synthesized by the microwave irradiation method. A 
long-chain ester moiety [2-(methacryloyloxy)ethyl] and 
various substituents on the phenyl ring were demonstrated 
to aff ect the muscle relaxant activity occurring in isolated 
rabbit gastric fundus smooth muscle strips. Forced photo-
degradation conditions were applied to the molecules ac-
cording to the ICH rules. The degradation profi le of the 
drugs was monitored by spectrophotometry coupled with 
the multivariate curve resolution technique. Formation of 
the oxidized pyridine derivative was observed for all the 
studied DHPs, except for one compound, which showed 
very fast degradation and formation of a second photo-
product. Pharmacological tests on the molecules showed a 
good muscle relaxing eff ect, with a mechanism similar to 
that of nifedipine, however, proving to be more stable to 
light.
Keywords:  1,4-dihydropyridine compounds, muscle relax-
ant, drug design, structure activity relationship, photosta-
bility, MCR analysis
1,4-Dihydropyridines (DHPs) are an important class of calcium channel blockers. 
These compounds are considered to be vital drugs against cardiovascular diseases such 
as hypertension and angina pectoris (1). Besides the main cardiovascular actions, the 1,4-
DHP nucleus has been shown to possess potential anti-tuberculosis, antioxidant, analge-
sic, anti-tumor and anti-microbial activity (2–4).
Numerous changes have been proposed for the basic structure of the parent drug 
nifedipine (NIF) in order to strengthen the modulating eff ects on calcium channels (5, 6). 
According to several structure-activity relationship studies, the 1,4-dihydropyridine ring 
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(7). The presence of one or more electron-att racting substituents at the ortho- or meta-posi-
tion of the phenyl ring increases the activity (8). Ester groups at C-3 and C-5 are in turn 
very important for modulating activity and tissue selectivity. Most att empts to optimize 
the activity of DHPs are focused on these ester groups. In condensed 1,4-DHPs, modifi ca-
tion of the ester moiety is essential in blocking the calcium channels (9, 10). Recent studies 
describe the importance of long chain esters with aromatic/hydrophobic groups in obtain-
ing potent calcium blockers such as nicardipine, azelnidipine and cilnidipine (4). Fused 
DHPs obtained by introducing the DHP ring into condensed ring systems have shown 
good calcium antagonistic eff ects (11, 12). Recently, a series of new condensed 1,4-DHP 
derivatives, having a dimethyl-substituted cyclohexane ring fused with a 3-pyridylmethyl 
moiety, have been synthesized by our research groups (13, 14).
In this work, a series of new condensed DPH analogues were synthetized by the mi-
crowave irradiation method. The muscle relaxant activity of these compounds was evalu-
ated on isolated rabbit gastric fundus smooth muscle strips and compared to that of NIF. 
Due to the well-known photo-lability of DHPs (15–18), the synthesized compounds were 
subjected to photodegradation tests (19). Concentration of parent compounds and by-prod-
ucts was calculated by multivariate curve resolution-alternating least squares (MCR-ALS) 
applied to the spectral data (20–22).
EXPERIMENTAL
Chemicals and materials
All chemicals used were purchased from Aldrich and Fluka (USA) and were used 
without further purifi cation. Reactions to obtain the target compounds were carried out 
in a Discover microwave apparatus (CEM, USA). Purity of the obtained compounds was 
initially checked using thin layer chromatography (TLC) on Merck aluminium sheets 
(Germany), silica gel 60 F254, mobile phase ethyl acetate-hexane (1:1), and UV absorbing 
spots were detected under short-wavelength (254 nm) light (Camag UV Cabinet, Ger-
many). Melting points were determined on a Thomas Hoover capillary melting point 
apparatus (USA) and were uncorrected. Infrared spectra (IR) were obtained on a Perkin 
Elmer Spectrum BX FT-IR (UK) equipped with MIRacle ATR accessory (PIKE Technolo-
gies, USA) and were reported in cm–1. 1H NMR and 13C NMR spectra were recorded in 
dimethyl sulfoxide (DMSO-d6) solutions on a Varian Mercury 400, 400 MHz high perfor-
mance digital FT-NMR spectrometer (USA) using tetramethylsilane (TMS) as internal 
standard. Chemical shift s were reported in parts per million (ppm). ESI-MS spectra were 
measured on a Micromass ZQ-4000 single quadrupole mass spectrometer (Waters, USA). 
Elemental analyses (C, H, N) were performed on a Leco CHNS-932 elemental analyzer 
(USA).
Photodegradation tests were performed using a light cabinet Suntest CPS+ (Heraeus, 
Italy). During the photodegradation experiments, UV spectra were recorded by means of 
a Perkin-Elmer Lambda 40P spectrophotometer (Artisan Technology Group, USA). UV 
WinLab® (Perkin-Elmer, USA) and Matlab® computer environment (Mathwork Inc., ver-
sion 7, USA) soft ware permitt ed spectral acquisition and multivariate analysis, resp.
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Synthesis of 2-(methacryloyloxy)ethyl-2,6,6-trimethyl-4-substituted phenyl-5-oxo-
1,4,5,6,7,8-hexahydroquinoline-3-carboxylates. General procedure
General procedure for the one-pot synthesis of 1,4-DHP derivatives via Hantzsch reac-
tion was as follows: 2 mmol 4,4-dimethyl-1,3-cyclohexanedione, 2 mmol substituted benz-
aldehyde, 2 mmol 2-(methacryloyloxy)ethyl acetoacetate and 10 mmol ammonium acetate 
were dissolved in a 35-mL microwave pressure vial in ethanol and subjected to microwave 
irradiation (power 75 W, maximum temperature 150 °C) for 10 minutes. Reaction progress 
was monitored by TLC. Aft er completion of the reaction, the mixture was dried under 
reduced pressure and the resulting precipitate was recrystallized from the dichlorometh-
ane/ether mixture. All physicochemical and spectral data of the synthesized compounds 
are listed in Table I.
2-(Methacryloyloxy)ethyl 2,6,6-trimethyl-4-(2-fl uorophenyl)-5-oxo-1,4,5,6,7,8-hexahydro-
quinoline-3-carboxylate (DHP1). – The compound was obtained by the reaction of 4,4-di-
methyl-1,3-cyclohexanedione (280 mg), 2-fl uorobenzaldehyde (248 mg), 2-(methacryloy-
loxy)ethyl acetoacetate (428 mg) and ammonium acetate (770 mg) in ethanol. 
2-(Methacryloyloxy)ethyl 2,6,6-trimethyl-4-(3-chlorophenyl)-5-oxo-1,4,5,6,7,8-hexahydro-
quinoline-3-carboxylate (DHP2). – The compound was obtained by the reaction of 4,4-di-
methyl-1,3-cyclohexanedione (280 mg), 3-chlorobenzaldehyde (280 mg), 2-(methacryloy-
loxy)ethyl acetoacetate (428 mg) and ammonium acetate (770 mg) in ethanol. 
2-(Methacryloyloxy)ethyl 2,6,6-trimethyl-4-(3-fl uorophenyl)-5-oxo-1,4,5,6,7,8-hexahydro-
quinoline-3-carboxylate (DHP3). – The compound was obtained by the reaction of 4,4-di-
methyl-1,3-cyclohexanedione (280 mg), 3-fl uorobenzaldehyde (248 mg), 2-(methacryloy-
loxy)ethyl acetoacetate (428 mg) and ammonium acetate (770 mg) in ethanol. 
2-(Methacryloyloxy)ethyl 2,6,6-trimethyl-4-(3-nitrophenyl)-5-oxo-1,4,5,6,7,8-hexahydroqui-
noline-3-carboxylate (DHP4). – The compound was obtained by the reaction of 4,4-dimethyl-
1,3-cyclohexanedione (280 mg), 3-nitrobenzaldehyde (302 mg), 2-(methacryloyloxy)ethyl 
acetoacetate (428 mg) and ammonium acetate (770 mg) in ethanol. 
2-(Methacryloyloxy)ethyl  2,6,6-trimethyl-4-(3-cyanophenyl)-5-oxo-1,4,5,6,7,8-hexahydro-
quinoline-3-carboxylate (DHP5). – The compound was obtained by the reaction of 4,4-di-
methyl-1,3-cyclohexanedione (280 mg), 3-cyanobenzaldehyde (262 mg), 2-(methacryloy-
loxy)ethyl acetoacetate (428 mg) and ammonium acetate (770 mg) in ethanol. 
2-(Methacryloyloxy)ethyl 2,6,6-trimethyl-4-(2,3-dichlorophenyl)-5-oxo-1,4,5,6,7,8-hexahy-
droquinoline-3-carboxylate (DHP6). – The compound was obtained by the reaction of 4,4-di-
methyl-1,3-cyclohexanedione (280 mg), 2,3-dichlorobenzaldehyde (350 mg), 2-(methacry-
loyloxy)ethyl acetoacetate (428 mg) and ammonium acetate (770 mg) in ethanol. 
Pharmacological evaluation
Nω-nitro-L-arginine-methyl ester (L-NAME) hydrochloride, tetraethylammonium 
chloride, guanethidine and NIF were dissolved in distilled water. Synthesized compounds 
and indomethacin were dissolved in DMSO.
New Zealand white rabbits, weighing 2.5-3 kg, were used in the study. Rabbits were 
sacrifi ced by intravenous injection of sodium pentobarbital (30–40 mg kg–1 bm), followed 
by removal of the stomach through abdominal incision. The fundal part of the stomach 
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was then dissected parallel to the longitudinal muscle wall. One muscle strip, approxi-
mately 15–20 mm long and 2 mm wide, was obtained and allowed to equilibrate for a pe-
riod of 60 min in 20 mL organ bath fi lled with Krebs-Henseleit solution (KHS). The com-
position of the Ca2+-free Krebs solution was as follows (in mmol L–1): NaCl 118; KCl 4.7; 
NaHCO3 25; MgCl2 0.54; NaH2PO4 0.9; glucose 10.04. The solution was gassed with 95 % O2 
and 5 % CO2 during the study and temperature was maintained at 37 °C by a thermo-
regulated water circuit. The pH of the saturated solution was 7.4. Each strip was connected 
to a force transducer (FDT 10-A, May IOBS 99, COMMAT Iletisim Co., Turkey) for the mea-
surement of isometric force, which was continuously displaced and recorded on an online 
computer via a four-channel transducer data acquisition system (MP30B-CE, BIOPAC Sys-
tems Inc., USA) using soft ware (BSL PRO v 3.6.7, BIOPAC Systems Inc. Santa Barbara, CA, 
USA) which had the capacity to analyse the data. Aft er mounting, each strip was allowed 
to equilibrate with a basal tension of 1 g for 60 min. KHS was replaced with fresh solution 
every 15 min during that period.
To eliminate that the relaxation induced by the test compounds was due to an interac-
tion with cyclooxygenase, potassium channels, adrenergic or nitric oxide pathways, all 
experiments were done in the presence of indomethacin (COX inhibitor, 10–5 mol L–1), tet-
raethylammonium chloride (non-specifi c K+ channel blocker, 10–4 mol L–1), guanethidine 
(adrenergic nerve blocker, 10–6 mol L–1) and Nω-nitro-L-arginine methyl ester hydrochlo-
ride (nitric oxide synthase inhibitor, 10–4 mol L–1).
When Ca2+ (2.5 mmol L–1) was added to the organ bath, a contraction developed. At the 
plateau level of contraction, compounds DHP1-DHP6 (10–8–10–4 mol L–1) and nifedipine 
(10–10–10–7 mol L–1) were applied. Concentration-relaxation relationship for compounds 
and nifedipine was observed by adding them into the bath in a cumulative manner. Re-
sponses to the test compounds and nifedipine were expressed as percentage of the pre-
contraction using Ca2+ (2.5 mmol L–1). The muscle relaxant activities of DHP1-DHP6 and of 
NIF, as a reference, were evaluated by measuring the values of maximum relaxant eff ects 
(Emax, %) and the negative logarithm of the half-maximal eff ective concentration EC50 (in 
mol L–1) (pD2) on isolated rabbit gastric fundus smooth muscle strips according to the 
method reported in the literature (13). The cited values were calculated from the concen-
tration-response curve obtained in each experiment, as predicted from the Scatchard 
equation for drug-receptor interaction, where:
response/concentration = (1/EC50) x response + maximum response/EC50
All data are expressed as mean ± standard error. Statistical comparison between the 
groups was performed using the Mann-Whitney U-test and p < 0.05 indicated statistical 
signifi cance (Vaghy, 1987 #1030).
Dimethyl sulphoxide (DMSO) was also tested in Ca2+ (2.5 mmol L–1) pre-contracted 
strips. The compounds were dissolved in dimethyl sulfoxide (DMSO) (< 0.01 %). These 
concentrations of DMSO had no eff ect on gastric fundus smooth muscle strips pre-treated 
with Ca2+ (2.5 mmol L–1).
The study was approved by the Ethics Committ ee of Gazi University, Faculty of Med-
icine, Ankara, Turkey. All procedures involving animals and their care were conducted in 
conformity with international laws and policies.
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Photodegradation studies
The light cabinet Suntest CPS+ was chosen for the photodegradation experiments. The 
apparatus is equipped with a xenon lamp able to simulate sunlight. Temperature and ir-
radiation were kept constant inside the cabinet and were measured with an electronic 
device. A standard fi lter ID65 provided a spectral window in the range of 300–800 nm, in 
agreement with option 1 of ICH rules (19). The samples were irradiated under irradiance 
power of 21 kJ m–2 min–1 and at constant temperature of 25 °C. Parameters for recording 
the UV spectra were: scan rate 1 nm s–1, time response 1 s, spectral band 1 nm, wavelength 
range 200–450 nm. The spectra were recorded at time 0 and at sequential time points: 1, 3, 
5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 70, 80, 90, 100, 120, 130, 140, 150, 160, 170, 180, 190, 
200, 230, 260, 300, 350 and 420 min. Each photodegradation test was performed six times. 
The collected spectral data were averaged from six experiments. SD was calculated by 
MCR elaboration applied to the data.
Chemometric elaboration
UV spectrophotometric data matrices from the photodegradation experiments were 
processed by MCR-ALS, a recent chemometric technique allowing the study of a complex 
chemical process. Its application to UV spectral data can resolve the whole system, esti-
mating the number of components, their pure spectra and concentration profi les. Rate 
constants (k) are also calculated in the processing of kinetic reactions. Analogously with 
other multivariate methods, MCR makes it possible to decompose the experimental data 
matrices into the contributions of individual components. The data matrices contain the 
recorded absorption spectra as a function of the evolution of the chemical process (time, 
reaction conditions, etc.). Details on the theory of MCR-ALS and its application on drug 
matrices are fully described in some papers (23–25).
RESULTS AND DISCUSSION
Chemistry
In our previous study, several condensed DHP derivatives were synthesized via a 
modifi ed Hantzsch reaction, bearing a cyclopentane, cyclohexane or tetrahydrothiopene 
ring with a bulky and lipophilic moiety (3-pyridylmethyl) in the ester group (13). Hantzsch 
reaction is the one-pot classical method for the synthesis of 1,4-DHPs, which involves cy-
clocondensation of an aldehyde, two equivalents of a 1,3-dicarbonyl compound and am-
monia, generally in refl uxing ethanol. Depending on the reaction conditions, long reaction 
times, low yields and unexpected products can occur (26, 27).
In this work, target compounds were achieved by the reaction of 4,4-dimethyl-1,3-cy-
clohexanedione, substituted benzaldehyde, 2-(methacryloyloxy)ethyl acetoacetate and am-
monium acetate in ethanol, according to a modifi ed Hantzsch reaction, by adopting a micro-
wave-assisted one-pot method. Microwave (MW) irradiation represents a novelty of the 
synthetic strategy due to its ability of reducing reaction times, improving yields and simpli-
fying the work-up processes (28, 29). The synthetic route used is outlined in Scheme 1.
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Structures of all compounds were elucidated by spectral methods (IR, 1H NMR, 13C 
NMR and mass spectrometry) and confi rmed by elemental analysis. In the IR spectra, a 
characteristic N-H stretching band appeared at about 3300 cm–1. Ester and ketone C=O 
stretching bands were seen at about 1700 and 1650 cm–1, respectively. Also, the characteristic 
stretching band of cyano group in the IR spectrum of DHP5 was observed at 2229 cm–1.
In the 1H NMR spectra, signals of methyl protons at the 6-position of the hexahydro-
quinoline ring were observed at 0.79–1.01 ppm, separately as singlets. The characteristic 
two signals of the diastereotopic methylidene protons of the ester group were at 5.63–5.98 
ppm, while the N-H proton signal was observed at 9.15–9.29 ppm. Chemical shift s of the 
aromatic, aliphatic and DHP ring protons were seen at expected values.
The 13C NMR spectra of the compounds displayed the appropriate number of reso-
nances, which exactly fi tt ed the number of carbon atoms. The signal of the carbonyl group 
at C-5 of the hexahydroquinoline ring appeared at about 200 ppm while the ester carbonyl 
groups were seen close to 167 ppm. The eff ect of resonance and the inductive eff ect of nitro-
gen atom caused a great diff erence in the chemical shift  between sp2 hybridized carbons of 
the DHP ring, as the C-2 and C-8a were observed more deshielded at around 150 ppm, while 
C-3 and C-4a appeared at 102 and 109 ppm, resp. The peaks of vinyl carbons of the ester 
group were seen at about 126 and 136 ppm. Two characteristic signals of aliphatic carbons 
att ached to oxygens in methacryloyloxy ester (ester adjacent aliphatics) appeared at around 
63 and 61 ppm. In addition, the signal of the cyano group (CN) in DHP5 appeared at 111 
ppm. 13C NMR chemical shift  data of DHP1-DHP6 are given in Table II.
Mass spectra of the compounds were recorded via the electrospray ionization tech-
nique. The quasimolecular ions created by the addition of sodium ion [M+Na]+ were ob-
served in the spectra of all compounds. Cleavage of the ester group and the phenyl ring 
from the parent molecule are further the most observed fragmentations. The isotope eff ect 
of chlorine atom appeared obviously in DHP2, carrying one chlorine atom, as [M+Na+2]+ 
with a relative ratio 66 %, while in DHP6, with two chlorine atoms, observed as two peaks 
[M+Na+2]+ and [M+Na+4]+ with relative ratios 66 and 11 %, respectively.
Pharmacological activity
The muscle relaxant activities of the new DHPs and of NIF, as a reference, were evalu-
ated by measuring the values of maximum relaxant eff ects (Emax, %) and the negative 
logarithm of EC50 (in mol L–1) (pD2) on isolated rabbit gastric fundus smooth muscle strips. 
Scheme 1.
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Chemical structures of the analyzed compounds and the relative Emax and pD2 values are 
given in Table III.
The results indicated that all the tested compounds exerted concentration-dependent 
relaxation on gastric fundus smooth muscle strips pre-treated with Ca2+ (2.5 mmol–1) in the 
following effi  cacy order: NIF > DHP4 ≥ DHP1 ≥ DHP5 > DHP6 = DHP3 = DHP2. These re-
sults show that the studied compounds exhibit comparable mutual effi  cacy and potency; 
however, in comparison with NIF, the effi  cacy is on average signifi cantly lower, while the 
potency is signifi cantly higher, possibly due to the blockade of calcium channels.
Given that the diff erence between the compounds is the aromatic substitution patt ern, 
this suggests that the substituents on the phenyl ring play a key role in the ability of these 
compounds to possess myorelaxant eff ects. When the obtained results are analyzed in 
terms of the substituents on the phenyl ring at the C-4 position of DHP, the most active 
derivative was found to be the 3-NO2 analogue (DHP4). Regarding the R2 substituent, the 
compounds bearing strong electron withdrawing groups (NO2, CN) were observed to be 
the most active derivatives. Displacement of the fl uorine atom from meta (R2) to ortho (R1) 
position increased the preferential activity. Introduction of the second chlorine atom on 
the phenyl ring mediated no signifi cant change in myorelaxant activity.
Table III. Chemical structures and maximum relaxant responses (Emax) and pD2 values of DHP1-DHP6 and 
NIF on isolated rabbit gastric fundus smooth muscle strips
DHP R1 R2 Emax (%)a pD2 a
1 F H 75.09 ± 5.95* 5.19 ± 0.47*
2 H Cl 66.83 ± 4.53* 5.29 ± 0.36*
3 H F 67.98 ± 6.58* 5.22 ± 0.52*
4 H NO2 79.01 ± 4.03* 5.28 ± 0.30*
5 H CN 73.60 ± 6.99* 5.16 ± 0.54*
6 Cl Cl 68.48 ± 1.88* 5.46 ± 0.03*
NIF – – 98.92 ± 0.83 7.68 ± 0.08
Relaxation is expressed as percentage of pre-contraction induced by Ca2+ (2.5 mmol L–1).
pD2 is a negative logarithm of the concentration for the half-maximal response EC50 (mol L–1).
a Mean ± SEM, n = 6.
Signifi cant diff erence compared to NIF: *p < 0.05.
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It was also proven that there was no contribution of cyclooxygenase, adrenergic and 
nitric oxide pathways, ATP sensitive K+ channels and Ca-activated K+ channels to the myo-
relaxant eff ects of these compounds.
Photostability study
All drugs belonging to the DHP class show a remarkable sensitivity to light, posing 
serious limits to easy handling of their pharmaceutical preparations. Several reports evi-
dence the photolability of DHPs used in therapy (15–18). Photodegradation tests of the 
newly synthesized compounds were performed with the aim to identify DHP structures 
more photostable than the currently known congeners. DHP molecules more resistant to 
light could be candidates for preparing liquid formulations of these drugs, currently hin-
dered by their photolability.
In our previous studies (14–16, 30–32), the infl uence of sample concentration on the 
photodegradation profi le was demonstrated. However, in this study, degradation kinetics 
and the number of photoproducts remained unchanged with increasing concentration of 
analytes. Thus, photostability studies were applied to standard ethanolic solutions of the 
synthesized DHPs at a concentration of 20 μg mL–1, which was optimal for spectrophoto-
metric measurements at time 0 and at several time points, as described above. Stress tests 
were performed in agreement with option 1 of ICH rules (19).
All samples, except sample DHP4, showed the same degradation profi le. Fig. 1 shows 
the spectral sequences for samples DHP1 and DHP4, as representatives. Gradual decreases 
of absorbance signals of the DHP chromophoric group were observed in regions 340–400 
and 230–250 nm. Simultaneous appearance and increase of a new peak in region 260–310 nm 
was observed, which was due to the formation of the pyridine group, in agreement with 
our previous studies (14–16). The sequence of the recorded spectra for all studied com-
pounds evidenced the formation of photodegradation products. The collected spectra fur-
nished the temporal spectral evolution of the system without any specifi cations about all 
species involved in the chemical process. Characterization of the components involved in 
the photodegradation process, therefore, required the application of chemometric methods 
to the data matrices. According to our previous work (14), the residual concentration of the 
target compounds was determined by applying the MCR algorithm to the spectral data. 
Fig. 1. Absorbance spectra of DHP1 and DHP4 solutions (20 μg mL–1) during irradiation.
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This chemometric procedure was adopted for its ability to determine, during the entire 
photodegradation process, the number of involved species and their concentration and at 
the same time to plot their absorbance spectra (20–22).
Fig. 2 shows the photodegradation profi le of all the studied DHPs, obtained by plot-
ting residual concentrations vs. sequential irradiation times throughout the photodegrada-
tion experiments.
All tested compounds were confi rmed to be sensitive to light, showing 10 % degrada-
tion in less than twenty minutes of irradiation. Although the degradation process was still 
fast, the new molecules were much more stable than NIF. This result is very important 
when considering the toxicity of DHP by-products. Phototoxic skin responses aft er sys-
temic administration of photosensitive drugs have been reported (33). Exposure to light of 
DHP has been demonstrated to cause signifi cant production of singlet oxygen, superoxide, 
or both, indicating their phototoxic potential of inducing dermatitis.
Spectral data collected during the photodegradation tests, an average of six experi-
ments, were processed by MCR-ALS to calculate the concentration profi les of all the spe-
cies detected during the degradation process and to predict their absorbance spectra. Stan-
dard deviation of the found concentrations was between 0.01–0.09 μg mL–1. Fig. 3 shows 
the estimated concentration profi les of DHP1 and DHP4, with their by-products and the 
respective absorbance spectra.
All the photodegradation processes followed fi rst-order kinetics, according to the 
equation: 
log (% DHP) = –k .t + 2
in which % DHP was the residual drug percentage, k the rate constant, t the time (s) and 
value 2 represented the logarithm of the initial concentration (100 %). The time to cause 
10 % degradation (t0,1), the number of the involved species in the kinetic process and lack 
Fig. 2. Photodegradation profi les of all DHP molecules (20 μg mL–1) exposed to light.
352
M. G. Gündüz et al.: Synthesis and photodegradation studies of analogues of muscle relaxant 1,4-dihydropyridine compounds, Acta 
Pharm. 67 (2017) 341–355.
 
Fig. 3. Absorbance spectra and concentration profi les of DHP1 (a and b, resp.) and DHP4 (c and d, 
resp.) and their by-products from MCR elaboration.
Table IV. Degradation kinetics parameters for DHP1-DHP6
DHP No. species k ± SD) × 10
3
(μg mL–1 min–1)a LOF (%) t0.1 (min)
1 2 7.00 ± 0.09 5.48 15.30
2 2 5.70 ± 0.02 2.39 19.27





5 2 7.20 ± 0.05 4.16 15.25
6 2 14.30 ± 0.34 8.05 7.42
No. species – number of species involved in the kinetic process, k – photodegradation rate constant, LOF – lack of 
fi t, t0.1 – time to cause 10 % degradation
a Number of replicate measurements, n = 6.
of fi t (LOF, %) were calculated as well. Singular value decomposition (SVD) techniques 
were applied to spectral data matrices to defi ne the number of the species involved in the 
photodegradation process. SVD is a mathematical procedure commonly used in the analysis 
      a)                                                                           b)
       c)                                                                                           d)
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of spectroscopic data to diff erentiate signals from noise and to reduce the dimensionality 
of subsequent least-squares fi ts. SVD takes data from experiments under diff erent condi-
tions, such as time or pH, and represents them by two sets of vectors weighted by their 
corresponding singular values. Table IV summarizes all the calculated kinetic parameters, 
as an average of six determinations. Very low values of variance were found in all the 
cases.
Formation of a single photoproduct (P1), corresponding to the pyridine derivative 
according to the literature (14–18), was calculated for all the studied compounds. Only 
compound DHP4 showed diff erent behavior with the probable formation of the fi rst deg-
radation product (P1), followed by a secondary photoproduct (P2), as indicated by the 
number of species involved in the kinetic process, obtained by SVD data elaboration, and 
by the presence of two k values. Fast and complex degradation of compound DHP4 was 
probably due to the presence of the NO2 group on the phenyl ring, promoting an intramo-
lecular disproportionation reaction, followed by aromatization of the pyridinic ring, in 
agreement with the results reported in previous works (14, 16).
CONCLUSIONS
An easy, rapid and convenient method for the preparation of condensed 1,4-DHPs via 
a modifi ed Hantzsch reaction under MW irradiation is reported. Pharmacological evalua-
tion showed good relaxing eff ects on isolated rabbit gastric fundus smooth muscles, due 
to the blockade of Ca2+ channels, with a mechanism similar to that of NIF. A long-chain 
alkyl moiety [2-(methacryloyloxy)ethyl] as the ester function in combination with electron-
withdrawing substituents at the phenyl ring led to an increase in pharmacological activity.
Photostability of the synthesized compounds was also evaluated by a joint spectro-
photometric and chemometric approach with the aim to select light-stable drug candidates 
endowed with high pharmacological activity. The obtained results demonstrated a sig-
nifi cant increase of the photostability with halogen as substituent R2 of the phenyl ring 
with simultaneous absence of substituent in R1 position. 
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